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OBJECTIVE — Increased serum ferritin levels and iron stores may be involved in the devel-
opmentofabnormalglucosetoleranceinwomenpresentingwithobesityand/orpolycysticovary
syndrome (PCOS). We aimed to study the determinants of serum ferritin levels in premeno-
pausal women among indexes of insulin resistance, adiposity, hyperandrogenism, and geno-
types pertaining to inﬂammation, oxidative stress, and iron metabolism.
RESEARCH DESIGN AND METHODS — A total of 257 premenopausal women, clas-
siﬁed depending on the presence or absence of PCOS, obesity, and/or abnormal glucose toler-
ance, underwent a complete metabolic evaluation, serum ferritin, haptoglobin, and C-reactive
protein (CRP) measurements, and genotyping for proinﬂammatory and prooxidant variants and
mutations in the HFE gene.
RESULTS — Serum ferritin concentrations were increased in women presenting with PCOS
and/or abnormal glucose tolerance, independent of obesity. A stepwise multivariate linear re-
gression analysis (R
2  0.18, P  0.0001) retained menstrual dysfunction (0.14, P 
0.035), free testosterone (0.14, P  0.052), insulin sensitivity index ( 0.12, P 
0.012), the His63Asp variant in HFE (0.16, P  0.008), and abnormal glucose tolerance
(0.15, P  0.015) as signiﬁcant predictors of the logarithm of ferritin levels, whereas CRP,
haptoglobin, waist-to-hip ratio, or variants in the TNF, TNFRSF1B, IL6, IL6ST, IL6R, PON1,
and HFE Cys282Tyr mutation exerted no inﬂuence.
CONCLUSIONS — Androgen excess (partly because of hyperandrogenemia and partly be-
cause of menstrual dysfunction), insulin resistance, abnormal glucose tolerance, and the HFE
His63Asp variant correlate with ferritin levels in premenopausal women.
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M
ountingevidencesuggeststhatin-
creased body iron stores are in-
volved in the pathogenesis of
insulin-resistant disorders such as the
metabolic syndrome and type 2 diabetes
in the general population (1). This in-
volvementappearstobebidirectional,be-
cause not only does iron accumulation
favor insulin resistance and may contrib-
ute to pancreatic -cell dysfunction and
diabetes, but also insulin resistance may
inturnfacilitateironaccumulationwithin
the body (2,3). Interestingly, oxidative
stress and inﬂammation are involved in
the interplay between iron overload and
insulin resistance (2,4).
Although most of the evidence link-
ing iron metabolism and disorders of glu-
cose metabolism has been provided from
the study of middle-aged or older men
and of postmenopausal women (2,5),
body iron stores also inﬂuence insulin re-
sistance and glucose metabolism in pre-
menopausal women (6,7).
Ferritin is the cellular storage protein
foriron.Wehavereportedthatserumfer-
ritin levels are increased in women pre-
senting either with obesity or polycystic
ovary syndrome (PCOS) and especially
when both conditions are present in the
same patient (6). Therefore, both andro-
gen excess and insulin resistance may un-
derlie this ﬁnding. In addition, because
these changes occurred independent of
changes in serum inﬂammatory markers,
the increased ferritin level indicates that
body iron stores are actually increased in
these women and do not result from the
secondary role of ferritin as an acute-
phase marker (6).
Of note, serum ferritin levels were
clearly increased in the small subset of
these women presenting with abnormal
glucose tolerance, both in the PCOS and
nonhyperandrogenic subgroups (6). This
ﬁnding suggests that increased body iron
stores could be related to the develop-
ment of abnormalities in glucose metabo-
lisminthesepatients,becauseprogressive
ironaccumulationinthepancreasisarec-
ognized pathogenic mechanism of disor-
ders of glucose tolerance in patients with
iron overload (8).
We hypothesized that the reduced
menstrual losses due to the oligomenor-
rhea present in most women with PCOS
could contribute to their increased iron
stores, yet recent data from our group
suggest that insulin resistance is actually
one of the major players explaining their
increased serum ferritin levels: whereas
serum ferritin levels did not change after
restoring regular menses by using an oral
contraceptive for 6 months, these levels
decreased markedly after insulin sensiti-
zation with metformin (3).
The present study was undertaken
with the aim of identifying, in a large se-
ries of premenopausal women, the deter-
minants of increased serum ferritin levels
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factor for the development of abnormali-
ties of glucose tolerance) among markers
of hyperandrogenism, adiposity, insulin
resistance, and genomic variants related
to chronic inﬂammation, oxidative stress,
and iron metabolism.
RESEARCH DESIGN AND
METHODS— A total of 257 premeno-
pausal women were included. The group
was composed of consecutive patients re-
porting to the Department of Endocrinol-
ogy because of PCOS and/or weight excess
and of healthy nonhyperandrogenic nono-
bese volunteers recruited from the staff of
Hospital Universitario Ramo ´n y Cajal.
Women were classiﬁed according to their
BMI into obese (BMI 30 kg/m
2,n128)
and nonobese (BMI 30 kg/m
2, n  129)
subgroups. PCOS was diagnosed in 149
women presenting with clinical and/or bio-
chemical hyperandrogenism in addition to
oligo-ovulation as reported previously (9),
thereby fulﬁlling all of the current deﬁni-
tions of the syndrome (10–12), whereas
108womenshowednosignofhyperandro-
genism, had normal androgen levels, and
had regular ovulatory menstrual cycles.
Menstrual and ovulatory dysfunction
were deﬁned by the presence of oligo-
menorrhea(cycleslongerthan35days)or
amenorrhea (absence of menstrual bleed-
ing for at least three usual cycle lengths)
or, in women presenting with regular
menstrual cycles (cycles between 26 and
35 days), by lack of ovulation according
to body temperature charts and/or serum
progesterone levels  12.7 nmol/l during
thelutealphaseofthemenstrualcycle(9).
None of the women had a personal
history of hypertension, diabetes, or car-
diovascular events. Women who took
oral contraceptives, antiandrogens, insu-
linsensitizers,ironsupplements,ordrugs
that might interfere with blood pressure
regulation, lipid proﬁle, or carbohydrate
metabolismwithintheprevious6months
or who were referred for any medical rea-
son aside from androgen and/or weight
excess were automatically excluded.
Written informed consent was obtained
from all of the participants, and the study
was approved by the ethics committee of
Hospital Universitario Ramo ´n y Cajal.
Clinical and anthropometric vari-
ables, including the hirsutism score, BMI,
waist circumference, and waist-to-hip ra-
tio (WHR) were determined. WHR was
calculated by dividing the minimal waist
circumference by the hip circumference
at the level of the greater trochanters, us-
ing a nonstretchable measuring tape.
Whole blood, serum, and plasma
samples were obtained between days 5
and10ofthemenstrualcycle,orduring
amenorrhea after pregnancy was ex-
cluded. After a 3-day 300-g carbohy-
drate diet and 12-h overnight fasting,
samples were obtained early in the
morning for the measurement of total
testosterone, sex hormone–binding
globulin, 17-hydroxyprogesterone, an-
drostenedione, dehydroepiandros-
terone sulfate, luteinizing hormone,
follicle-stimulating hormone, estradiol,
thyrotropin, and prolactin. A complete
hemogram and serum biochemistry and
lipid proﬁles were also obtained. Then,
a 75-g oral glucose tolerance test was
performed, and samples were obtained
for measurement of serum insulin and
plasmaglucoseat0,30,60,90,and120
min. Samples were immediately centri-
fuged, and serum and plasma were
separated and frozen at 20°C until
assayed.
The assays used for these measure-
ments have been described in detail else-
where (9). Free testosterone concentrations
were calculated from total testosterone and
sex hormone–binding globulin levels (9).
SerumferritinandC-reactiveprotein(CRP)
concentrations were measured by auto-
mated immunochemiluminescence (Im-
mulite 2000 Ferritin and High Sensitivity
CRP;DiagnosticProductsCorporation,Los
Angeles, CA) with lower limits of detection
of 0.88 pmol/l and 0.1 mg/l, respectively,
andintra-andinterassaycoefﬁcientsofvari-
ation 10%. The circulating concentra-
tions of haptoglobin were assayed by a
commercialimmunonephelometrymethod
(Dade Behring, Marburg, Germany), cali-
brated against the international CRM 470
reference material. The composite insulin
sensitivity index was calculated from circu-
lating glucose and insulin concentrations
during the oral glucose tolerance test as de-
scribed by Matsuda and DeFronzo (13).
Disorders of glucose tolerance were diag-
nosed following the recommendations of
the American Diabetes Association (14).
DNA analysis
Genomic DNA was obtained from whole
blood samples using a Nucleon BACC3
DNA isolation kit (Amersham, Bucking-
hamshire, U.K.) and was used to geno-
type several polymorphisms related to
inﬂammation or oxidative stress that had
been previously found to be associated
with metabolic disorders such as PCOS,
obesity, diabetes, and insulin resistance
andvariantsinvolvedinironmetabolism.
GenotypingofthedinucleotideCArepeat
inintron8oftheinterleukin(IL)-6recep-
tor- (IL6R) locus (rs57636717) was
performed by PCR using a ﬂuorescently
labeled forward primer (15). Ampliﬁed
fragmentswereresolvedbycapillaryelec-
trophoresis on an ABI Prism 3100 auto-
mated genetic analyzer (Applied
Biosystems, Foster City, CA), and their
sizesweredeterminedusingGeneMapper
4.0 software. We detected 13 different al-
leles with sizes ranging from 143 to 169
bp, of which the 149-bp allele was the
most frequent. For statistical analyses,
subjects were genotyped as homozygous
for 149-bp alleles, heterozygous for
149-bp alleles, and noncarriers of any
149-bp allele (15). Several genomic vari-
ants were analyzed by PCR–restriction
fragment–length polymorphism as de-
scribed previously: variants His63Asp
(c.187CG) and Cys282Tyr (c.845GA)
in exons 2 and 4 (rs1799945 and
rs1800562, respectively) of the HFE
gene (7); polymorphism 308GA
(rs1800629) in the promoter of the tumor
necrosis factor (TNF)- (TNF) gene (16);
variant Met196Arg (c.587TG;
rs1061622)inexon6oftheTNFreceptor2
(TNFRSF1B) gene (17); polymorphism
174GC (rs1800795) in the IL-6 gene
promoter (18); variant Gly148Arg
(c.442GC; rs2228044) in exon 5 of the
IL-6 signal transducer (IL6ST) gene (15);
and polymorphism 108CT (rs705379)
in the paraoxonase (PON1) gene (19).
Statistical analysis
Data are shown as means  SD unless
otherwise stated. The Kolmogorov-
Smirnov statistic was applied to continu-
ous variables. Logarithmic or square-root
transformations were applied as needed
to ensure normal distribution of the vari-
ables. Univariate general linear models
were used to evaluate the inﬂuence of
obesity, PCOS, and glucose tolerance on
clinical and biochemical variables, with
introduction of age as a covariate to con-
trolforpossibleagedifferencesamongthe
groups. A multivariate linear regression
analysis was used to determine the inﬂu-
ence of clinical, biochemical, metabolic,
and genetic variants on the logarithm of
serum ferritin concentrations as de-
scribed below. Depending on the median
of the whole population of premeno-
pausal women, serum ferritin levels were
categorized into values below, or equal to
or above, the median value. The associa-
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and continuous variables were analyzed
by 
2 and Fisher’s exact tests as appropri-
ate. P  0.05 was considered statistically
signiﬁcant. Analyses were performed us-
ingSPSSStatistics17(SPSS,Chicago,IL).
RESULTS— The inﬂuence of PCOS
andofobesityonclinicalandbiochemical
variables is summarized in Table 1. Be-
cause patients with PCOS were younger
than nonhyperandrogenic women and
obese women were older than nonobese
women, the inﬂuence of age was con-
trolled by introducing this variable as a
covariate in the comparisons described
below.
Patients with PCOS had increased se-
rum androgen and luteinizing hormone
levels and decreased estradiol concentra-
tions and were insulin resistant and had
increasedWHRcomparedwiththeirnon-
hyperandrogenic counterparts irrespec-
tive of obesity. Obesity was characterized
byincreasedindexesofinsulinresistance,
increased frequency of abnormalities in
glucose tolerance, and increased serum
CRP, haptoglobin, and free testosterone
levels compared with those in nonobese
women, both in patients with PCOS and
in nonhyperandrogenic women.
Serum ferritin levels were inﬂuenced
independently by PCOS and glucose in-
tolerance (Fig. 1). Patients with PCOS
presented with increased serum ferritin
levels compared with those in nonhy-
perandrogenicwomen.Whenconsidered
as a whole, women presenting with ab-
normal glucose tolerance had higher se-
rum ferritin concentrations compared
with those showing normal glucose val-
ues during fasting and after an oral glu-
cose tolerance test. Of note, these results
occurred both in the nonobese and in the
obese subgroups, and obesity did not in-
ﬂuence serum ferritin concentrations af-
tercontrollingforbothPCOSandglucose
tolerance (Fig. 1).
Becauseserumferritinlevelswerenot
distributed normally, their logarithm was
introduced as a dependent variable in
multiple linear regression models using
age; BMI; glucose tolerance (codiﬁed as
normal or abnormal); menstrual cycles
(codiﬁed as regular menstruation, oligo-
menorrhea, or amenorrhea); serum free
testosterone, CRP, and haptoglobin lev-
els; the insulin sensitivity index; and the
genomic variants related to iron metabo-
lism, inﬂammation, and oxidative stress
as independent variables. The model that
considered all independent variables ex-
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arithm of serum ferritin concentrations
(R
2  0.22, P  0.0001) (Fig. 2).
Conversely, when the independent
variables were introduced using a step-
wise method (probability to enter 0.05;
probability to remove 0.10), the model
(R
2  0.18, P  0.0001) retained only
menstrual dysfunction (0.14, P 
0.035), serum free testosterone levels
(0.14, P  0.052), insulin sensitivity
index(0.12,P0.012),His63Asp
variantinHFE(0.16,P0.008),and
abnormal glucose tolerance (0.15,
P  0.015) as signiﬁcant predictors of
the logarithm of serum ferritin levels,
whereas all the other clinical, biochemi-
cal, and genomic variables were excluded
(Fig.2).Finally,asimilarstepwiseregres-
sion method (R
2  0.17, P  0.0001)
adjusted for age and BMI (these variables
were manually entered into the model)
retainedonlymenstrualdysfunction(
0.18, P  0.003), abnormal glucose tol-
erance (0.17, P  0.013), His63Asp
variantinHFE(0.17,P0.004),and
insulinsensitivityindex(0.15,P
0.031) as predictors of the logarithm of
serum ferritin levels (Fig. 2).
When considering the median of the
serum ferritin concentrations of the
whole population (83 pmol/l) as a cutoff
value, premenopausal women presenting
with a serum ferritin level above the me-
dian had an odds ratio (OR) for abnormal
glucosetoleranceof2.4(95%CI1.3–4.4,

2  7.420, P  0.009) and an OR for
PCOS of 2.2 (1.3–3.7, 
2  9.524, P 
0.002).
CONCLUSIONS— The metabolic
consequences of iron overload are exem-
pliﬁed by the development of abnormali-
ties of glucose tolerance in primary or
secondary hemochromatosis. However,
less severe iron overload also plays an im-
portant role in the development of abnor-
malities in glucose tolerance (2), as
demonstrated by the improvement in in-
sulin resistance and glucose tolerance in
type 2 diabetic patients after the iron de-
pletionachievedbyrepeatedbloodletting
(20) or the higher insulin sensitivity asso-
ciated with reduced iron stores in fre-
quent blood donors from the general
population (21).
Our present results demonstrate that
serum ferritin levels, an accurate marker
ofbodyironstoresintheabsenceofacute
inﬂammatory syndromes (2), are also re-
lated to abnormal glucose tolerance in
premenopausal women. Serum ferritin
levels above the median were associated
with a 2.4-fold OR for presenting with
abnormal glucose tolerance, and ferritin
concentrations were clearly higher in
women in whom fasting or postload glu-
cose levels were above the normal range.
Furthermore, our present results suggest
that the body iron stores of premeno-
pausal women are associated with several
factors including menstrual dysfunction,
insulin resistance, and the His63Asp vari-
ant in HFE even after controlling for the
difference in age among patients with
PCOS and nonhyperandrogenic control
subjects and between obese and non-
obese women.
We have reported previously, in a
much smaller series, that body iron stores
are increased in premenopausal women
presenting with PCOS and obesity and
that these associations were independent
of mutations in HFE and were not inﬂu-
enced by changes in markers of chronic
inﬂammation (6,7). Our present ﬁndings
conﬁrm that serum ferritin levels are in-
creased in patients with PCOS and that,
accordingly, women presenting with se-
rum ferritin levels above the median have
a 2.2 OR of having PCOS. Yet when con-
trolling for the presence or absence of ab-
normal glucose tolerance, the previously
reported association with obesity disap-
pears, suggesting that it is the increased
prevalence of disordered glucose toler-
ance in obese women and not weight ex-
cess by itself that is responsible for
increased body iron stores in these
women.
According to the regression analyses
presented here, menstrual dysfunction,
increased androgen levels, and insulin re-
sistance, together with the HFE His63Asp
variant and abnormal glucose tolerance,
are among the strongest predictors of se-
rum ferritin levels. On the contrary, these
levels are not inﬂuenced by indexes of
global or abdominal adiposity or by
genomic variants related to chronic in-
ﬂammation and oxidative stress.
Therefore, it appears that androgen
excess and insulin resistance, which are
present in many patients with PCOS, col-
laborate in increasing body iron stores in
premenopausal women. The effects of in-
sulin resistance and hyperinsulinism on
bodyironstoresmightdependonadirect
insulinstimulationofintestinalironabsorp-
tion by upregulating activity of hypoxia-
inducible factor-1 and downregulating
hepcidin expression (22,23) and may be
counteracted in patients with PCOS by ad-
ministering insulin sensitizers (3).
Theeffectofandrogenexcessonbody
iron stores might result from the well-
knownstimulatoryeffectofandrogenson
erythropoiesis, thereby increasing intesti-
nal iron absorption (24) but may also re-
sult from the iron-sparing effect of
reduced menstrual losses due to the
chronic menstrual dysfunction of PCOS.
Figure 1—Serum ferritin levels depending on the presence or absence of abnormalities of glucose
tolerance and PCOS in nonobese   and obese u women. The box plot includes the median
(horizontal line) and the interquartile range, and the whiskers indicate the minimum and maxi-
mum data values, unless outliers are present, in which case the whiskers extend to a maximum of
1.5 times the interquartile range. The ﬁgures inside the boxes are the numbers of women in each
subgroup. The logarithm of serum ferritin levels was used in a general linear model in which
glucose tolerance, PCOS, and obesity were introduced as independent variables and age was
introduced as a covariate to correct for the difference in age between patients and control subjects
and between obese and nonobese women. No interaction was found among independent variables.
*P  0.001 between women presenting with or without abnormalities of glucose tolerance. †P 
0.034 between patients with PCOS and nonhyperandrogenic control women.
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years to result in increased iron stores,
explaining why regularization of men-
strual bleeding in patients with PCOS by
administering antiandrogenic contracep-
tive pills for 6 months had no evident
impactonserumferritinlevelsinourpre-
vious report (3).
Our present results also suggest that
the His63Asp variant in HFE inﬂuences
body iron stores in premenopausal
women, in conceptual agreement with
the partial loss of HFE function induced
by this mutation in animal models, lead-
ing to a variable degree of hepatic iron
loading (25). However, more impor-
tantly, the relatively strong association of
increased serum ferritin levels with ab-
normal glucose tolerance raises the possi-
bility that increased iron stores played
some pathogenic role in the development
of such metabolic derangements, given
that progressive iron accumulation in the
pancreas contributes to -cell dysfunc-
tion and abnormal glucose tolerance in
syndromesofironoverload(8).However,
because association does not imply cau-
sality, this hypothesis is speculative.
In summary, body iron stores, as re-
ﬂected by serum ferritin concentrations,
are interrelated with androgen excess, in-
sulinresistance,andtheHis63Aspvariant
in HFE in premenopausal women and are
associated with the development of ab-
normal glucose tolerance in this particu-
lar population.
Figure 2—Multiple linear regression analysis of the logarithm of serum ferritin concentrations. The squares are the standardized regression
coefﬁcients(,thechangeintermsofSDsinthedependentvariablethatresultsfromachangeof1SDinanindependentvariable),andtheerrorbars
indicatethe95%CIof.Menstrualhistoryandgenomicvariantswerecodedasdummyvariables:regularmenstruationwascoded0,1wasusedfor
oligomenorrhea,and2wasusedforamenorrhea.VariantsinTNF,TNFRSF1B,IL6,IL6ST,HFE,andPON1lociwerecodedas0forhomozygosity
for wild-type alleles, 1 for heterozygosity, and 2 for homozygosity for mutant alleles. The IL6R polymorphism was coded 0 for homozygosity for
149-bpalleles,1forsubjectscarryingonlyone149-bpallele,and2forsubjectscarryingtwonon–149-bpalleles.Finally,HFEHis63Asp/Cys282Tyr
double heterozygotes were coded 1 and subjects without double heterozygosity were coded 0.
Martínez-García and Associates
DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009 1529Acknowledgments— This study was sup-
ported by the Spanish Ministry of Science
and Innovation, Instituto de Salud Carlos III
(Grants FIS PI080944). Centro de Investiga-
ciones Biome ´dicas en Red de Diabetes y
Enfermedades Metabo ´licas Asociadas (CIB-
ERDEM) is an initiative of Instituto de Salud
Carlos III, Ministry of Science and
Innovation.
No potential conﬂicts of interest relevant to
this article were reported.
References
1. Tuomainen TP, Nyyssonen K, Salonen R,
Tervahauta A, Korpela H, Lakka T,
Kaplan GA, Salonen JT. Body iron stores
are associated with serum insulin and
blood glucose concentrations: population
study in 1,013 eastern Finnish men. Dia-
betes Care 1997;20:426–428
2. Fernandez-Real JM, Lopez-Bermejo A,
Ricart W. Cross-talk between iron metab-
olism and diabetes. Diabetes 2002;51:
2348–2354
3. Luque-Ramirez M, Alvarez-Blasco F,
Botella-Carretero JI, Sanchon R, San Mil-
lan JL, Escobar-Morreale HF. The in-
creased body iron stores of obese women
withpolycysticovarysyndromeareacon-
sequence of insulin resistance and hyper-
insulinism, and do not result from
reduced menstrual losses. Diabetes Care
2007;30:2309–2313
4. HirayamaM,KohgoY,KondoH,Shintani
N, Fujikawa K, Sasaki K, Kato J, Niitsu Y.
Regulation of iron metabolism in HepG2
cells: a possible role for cytokines in the
hepatic deposition of iron. Hepatology
1993;18:874–880
5. Jehn M, Clark JM, Guallar E. Serum fer-
ritin and risk of the metabolic syndrome
in U.S. adults. Diabetes Care 2004;27:
2422–2428
6. Escobar-Morreale HF, Luque-Ramirez M,
Alvarez-Blasco F, Botella-Carretero JI,
Sancho J, San Millan JL. Body iron stores
are increased in overweight and obese
women with polycystic ovary syndrome.
Diabetes Care 2005;28:2042–2044
7. Botella-Carretero JI, Luque-Ramirez M,
Alvarez-Blasco F, San Millan JL, Escobar-
Morreale HF. Mutations in the hereditary
hemochromatosis gene are not associated
with the increased body iron stores ob-
served in overweight and obese women
with polycystic ovary syndrome. Diabetes
Care 2006;29:2556
8. Dymock IW, Cassar J, Pyke DA, Oakley
WG, Williams R. Observations on the
pathogenesis, complications and treat-
ment of diabetes in 115 cases of haemo-
chromatosis.AmJMed1972;52:203-210
9. Escobar-Morreale HF, Sanchon R, San
MillanJL.Aprospectivestudyoftheprev-
alence of nonclassical congenital adrenal
hyperplasia among women presenting
with hyperandrogenic symptoms and
signs. J Clin Endocrinol Metab 2008;93:
527–533
10. Zawadzki JK, Dunaif A. Diagnostic crite-
ria for polycystic ovary syndrome: To-
wards a rational approach. In Polycystic
ovary syndrome. Dunaif A, Givens JR, Ha-
seltine FP, Merriam GR, Eds. Boston,
BlackwellScientiﬁcPublications,1992,p.
377–384
11. The Rotterdam ESHRE/ASRM-Sponsored
PCOS Consensus Workshop Group. Re-
vised 2003 consensus on diagnostic crite-
ria and long-term health risks related to
polycystic ovary syndrome (PCOS). Hum
Reprod 2004;19:41–47
12. Azziz R, Carmina E, Dewailly D, Dia-
manti-Kandarakis E, Escobar-Morreale
HF, Futterweit W, Janssen OE, Legro RS,
Norman RJ, Taylor AE, Witchel SF. Posi-
tion statement: criteria for deﬁning poly-
cysticovarysyndromeasapredominantly
hyperandrogenic syndrome: an Andro-
genExcessSocietyguideline.JClinEndo-
crinol Metab 2006;91:4237–4245
13. Matsuda M, DeFronzo RA. Insulin sensi-
tivity indices obtained from oral glucose
tolerancetesting:comparisonwiththeeu-
glycemic insulin clamp. Diabetes Care
1999;22:1462–1470
14. AmericanDiabetesAssociation.Diagnosis
and classiﬁcation of diabetes mellitus. Di-
abetes Care 2008;31(Suppl. 1):S55–S60
15. Escobar-MorrealeHF,CalvoRM,Villuen-
das G, Sancho J, San Millan JL. Associa-
tion of polymorphisms in the interleukin
6 receptor complex with obesity and hy-
perandrogenism.ObesRes2003;11:987–
996
16. Escobar-Morreale HF, Calvo RM, Sancho
J, San Milla ´n JL. TNF- and hyperandro-
genism: a clinical, biochemical and mo-
lecular genetic study. J Clin Endocrinol
Metab 2001;86:3761–3767
17. Peral B, San Millan JL, Castello R,
Moghetti P, Escobar-Morreale HF. The
methionine 196 arginine polymorphism
in exon 6 of the TNF receptor 2 gene
(TNFRSF1B) is associated with the poly-
cystic ovary syndrome and hyperandro-
genism. J Clin Endocrinol Metab 2002;
87:3977–3983
18. Villuendas G, San Millan JL, Sancho J, Es-
cobar-Morreale HF. The 597 G/A and
174 G/C polymorphisms in the pro-
moter of the interleukin 6 gene (IL6) are
associated with hyperandrogenism. J Clin
Endocrinol Metab 2002;87:1134–1141
19. San Millan JL, Corton M, Villuendas G,
Sancho J, Peral B, Escobar-Morreale HF.
Association of the polycystic ovary syn-
drome with genomic variants related to
insulin resistance, type 2 diabetes melli-
tus, and obesity. J Clin Endocrinol Metab
2004;89:2640–2646
20. Fernandez-Real JM, Penarroja G, Castro
A, Garcia-Bragado F, Hernandez-Aguado
I, Ricart W. Blood letting in high-ferritin
type2diabetes:effectsoninsulinsensitiv-
ity and beta-cell function. Diabetes 2002;
51:1000–1004
21. Fernandez-Real JM, Lopez-Bermejo A,
Ricart W. Iron stores, blood donation,
and insulin sensitivity and secretion. Clin
Chem 2005;51:1201–1205
22. McCarty MF. Hyperinsulinemia may
boost both hematocrit and iron absorp-
tion by up-regulating activity of hypoxia-
inducible factor-1. Med Hypotheses
2003;61:567–573
23. LeGuennoG,ChanseaumeE,RuivardM,
Morio B, Mazur A. Study of iron metabo-
lism disturbances in an animal model of
insulin resistance. Diabetes Res Clin Pract
2007;77:363–370
24. Berria R, Gastaldelli A, Lucidi S, Belfort R,
DeFilippisE,EastonC,BrytzkiR,CusiK,
Jovanovic L, DeFronzo R. Reduction in
hematocrit level after pioglitazone treat-
ment is correlated with decreased plasma
free testosterone level, not hemodilution,
in women with polycystic ovary syn-
drome. Clin Pharmacol Ther 2006;80:
105–114
25. Tomatsu S, Orii KO, Fleming RE, Holden
CC,WaheedA,BrittonRS,GutierrezMA,
Velez-Castrillon S, Bacon BR, Sly WS.
Contribution of the H63D mutation in
HFE to murine hereditary hemochroma-
tosis. Proc Natl Acad Sci U S A 2003;100:
15788–15793
Iron stores and glucose tolerance in women
1530 DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009